ArticleCancers2025

Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience.

Elena Alejo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.